MicroRNA Involvement in the Pathogenesis of Neuroblastoma: Potential for MicroRNA Mediated Therapeutics

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2009 Feb 10

PMID 19199973

Citations 42

Authors

R L Stallings

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma arises from precursor cells of the sympathetic nervous system and presently accounts for 15% of all childhood cancer deaths. These tumors display remarkable heterogeneity in clinical behavior, ranging from spontaneous regression to rapid progression and resistance to therapy. The clinical behavior of these tumors is associated with many factors, including patient age, histopathology and genetic abnormalities such as MYCN amplification. More recently, the dysregulation of some miRNAs, including the miR-17-5p-92 cluster and miR-34a, has been implicated in the pathobiology of neuroblastoma. MiR-17-5p-92 family members act in an oncogenic manner while miR-34a has tumor suppressor functions. The evidence for the contribution of miRNAs in the aggressive neuroblastoma phenotype is reviewed in this article, along with exciting possibilities for miRNA mediated therapeutics.

Citing Articles

Unsaturated Fatty Acid Synthesis Is Associated with Worse Survival and Is Differentially Regulated by and Tumor Suppressor microRNAs in Neuroblastoma.

Sheeter D, Garza S, Park H, Benhamou L, Badi N, Espinosa E Cancers (Basel). 2024; 16(8).

PMID: 38672672 PMC: 11048984. DOI: 10.3390/cancers16081590.

TTF1 suppresses neuroblastoma growth and induces neuroblastoma differentiation by targeting TrkA and the miR-204/TrkB axis.

Yang T, Li J, Zhuo Z, Zeng H, Tan T, Miao L iScience. 2022; 25(7):104655.

PMID: 35811845 PMC: 9263519. DOI: 10.1016/j.isci.2022.104655.

MicroRNAs in neural crest development and neurocristopathies.

Antonaci M, Wheeler G Biochem Soc Trans. 2022; 50(2):965-974.

PMID: 35383827 PMC: 9162459. DOI: 10.1042/BST20210828.

MicroRNA-323a-3p Negatively Regulates NEK6 in Colon Adenocarcinoma Cells.

Hong Z, Chen Z, Pan J, Shi Z, Wang C, Qiu C J Oncol. 2022; 2022:7007718.

PMID: 35096064 PMC: 8791743. DOI: 10.1155/2022/7007718.

MYCN in Neuroblastoma: "Old Wine into New Wineskins".

Braoudaki M, Hatziagapiou K, Zaravinos A, Lambrou G Diseases. 2021; 9(4).

PMID: 34842635 PMC: 8628738. DOI: 10.3390/diseases9040078.

References

Chen Y, Stallings R . Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007; 67(3):976-83. DOI: 10.1158/0008-5472.CAN-06-3667. View

Brinkschmidt C, Christiansen H, Terpe H, Simon R, Lampert F, Boecker W . Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol. 2001; 36(1):11-3. DOI: 10.1002/1096-911X(20010101)36:1<11::AID-MPO1004>3.0.CO;2-M. View

Kedde M, Strasser M, Boldajipour B, Vrielink J, Slanchev K, le Sage C . RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell. 2007; 131(7):1273-86. DOI: 10.1016/j.cell.2007.11.034. View

Schulte J, Horn S, Otto T, Samans B, Heukamp L, Eilers U . MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2007; 122(3):699-704. DOI: 10.1002/ijc.23153. View

Corney D, Flesken-Nikitin A, Godwin A, Wang W, Nikitin A . MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007; 67(18):8433-8. DOI: 10.1158/0008-5472.CAN-07-1585. View

Schramm A, Schulte J, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B . Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene. 2005; 24(53):7902-12. DOI: 10.1038/sj.onc.1208936. View

Chang T, Wentzel E, Kent O, Ramachandran K, Mullendore M, Lee K . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-52. PMC: 1939978. DOI: 10.1016/j.molcel.2007.05.010. View

Vandesompele J, van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P . Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998; 23(2):141-52. DOI: 10.1002/(sici)1098-2264(199810)23:2<141::aid-gcc7>3.0.co;2-2. View

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N . Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007; 26(5):731-43. DOI: 10.1016/j.molcel.2007.05.017. View

10.

Bommer G, Gerin I, Feng Y, Kaczorowski A, Kuick R, Love R . p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007; 17(15):1298-307. DOI: 10.1016/j.cub.2007.06.068. View

11.

Breen C, OMeara A, McDermott M, Mullarkey M, Stallings R . Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet. 2000; 120(1):44-9. DOI: 10.1016/s0165-4608(99)00252-6. View

12.

Attiyeh E, London W, Mosse Y, Wang Q, Winter C, Khazi D . Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005; 353(21):2243-53. DOI: 10.1056/NEJMoa052399. View

13.

Chang T, Yu D, Lee Y, Wentzel E, Arking D, West K . Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2007; 40(1):43-50. PMC: 2628762. DOI: 10.1038/ng.2007.30. View

14.

Wei J, Song Y, Durinck S, Chen Q, Cheuk A, Tsang P . The MYCN oncogene is a direct target of miR-34a. Oncogene. 2008; 27(39):5204-13. PMC: 2562938. DOI: 10.1038/onc.2008.154. View

15.

Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N . Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005; 23(10):2280-99. DOI: 10.1200/JCO.2005.06.104. View

16.

Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R . Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008; 582(10):1564-8. DOI: 10.1016/j.febslet.2008.03.057. View

17.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

18.

Zhang L, Huang J, Yang N, Greshock J, Megraw M, Giannakakis A . microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006; 103(24):9136-41. PMC: 1474008. DOI: 10.1073/pnas.0508889103. View

19.

Afanasyeva E, Hotz-Wagenblatt A, Glatting K, Westermann F . New miRNAs cloned from neuroblastoma. BMC Genomics. 2008; 9:52. PMC: 2254388. DOI: 10.1186/1471-2164-9-52. View

20.

Truckenmiller M, Vawter M, Cheadle C, Coggiano M, Donovan D, Freed W . Gene expression profile in early stage of retinoic acid-induced differentiation of human SH-SY5Y neuroblastoma cells. Restor Neurol Neurosci. 2002; 18(2-3):67-80. View